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ABSTRACT 
Helicobacter pylori classified as a class 1 carcinogen is a common human pathogen 
implicated in certain gastrointestinal diseases. Helicobacter pylori infection is acquired 
mainly in childhood, especially in developing countries. H. pylori infection causes peptic 
ulcer, duodenitis, gastritis and cancer. The growing resistance of H. pylori to antibiotics used 
in its treatment as well as other innate limitations of the triple therapy has necessitated a 
search for alternative treatment from natural sources which could be readily available, less 
cost effective. The antimicrobial activity of solvents (acetone, ethanol, methanol, chloroform 
and water) crude extracts of Lippia  javanica were investigated against 31 H. pylori strains by 
the agar well diffusion technique. The minimum inhibitory concentration (MIC) was 
determined by spectrophotometric analysis at 620 nm using the broth micro dilution method 
and the rate of kill by broth dilution method. Phytochemical analysis was also performed. H. 
pylori standard strain NCTC 11638 was included as a positive control. Metronidazole and 
amoxicillin were used as positive control antibiotics. The ANOVA test was used to analyze 
the results using SPSS version 17.0. The strains were inhibited by all the extracts with 
inhibition zones of diameter ranging from 0-36 mm and 0-35 mm for the control antibiotic, 
clarithromycin. The MIC90 ranged from 0.039- 0.625 mg/mL for acetone; 0.039-1.25mg/mL 
for methanol, 0.00195-0.313 mg/mL for ethanol; 0.01975-2.5 mg/mL for metronidazole and 
0.0048-2.5 mg/mL for amoxicillin. Acetone extract completely inhibited strain PE369C at 
MIC (0.1 mg/mL) and 2× MIC (0.2 mg/mL) in 18h and at ½× MIC (0.05 mg/mL) in 36h. 
Strain PE466C was completely inhibited at 4× MIC in 72h. Phytochemical analysis revealed 
the presence of flavonoids, saponins, tannins, steroids and alkaloids. The results indicate that 
the extracts of the leaves of L. javanica may contain compounds with anti-H. pylori activity 
and merits further study to identify the compounds.  
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CHAPTER ONE 
1.0 INTRODUCTION 
Helicobacter pylori is a helical shaped, Gram-negative, microaerophilic bacterium (2-4µm 
long with diameter of 0.5µm) that infects the stomach and duodenum (Sasaki et al., 1999). 
Infection with the organism may cause peptic ulcers, gastritis, duodenitis, and gastric cancer 
(Figueiroa et al.; 2002; Figueiredo et al., 2002; Ahmad et al., 2009). H. pylori chronically 
infects billions of people worldwide, is one of the most common chronic bacterial pathogens 
of humans and genetically diverse bacterial species. H. pylori infection with other bacteria is 
unclear however, H. pylori genes increases the risk of disease development, including those 
genes that encode exotoxins. The disease seems to result from an interaction between the 
bacterium, the host and the environment. Infections have been reported to be higher in the 
developing than in developed countries, especially in Africa (Rothenbacher and Brenner, 
2003; Ndip et al., 2007; Tanih et al., 2010). Interestingly, the organism has been reported to 
be prevalent in South Africa. For example, Pelser et al. (1997) documented a high prevalence 
of H. pylori antibodies (67-84%) in children in Bloemfontein, while Mosane et al. (2004) 
also documented H. pylori IgG antibodies in South African mothers and their children. 
H. pylori infection is often treated with a triple therapy, such as metronidazole (Mtz), 
clarithromycin or amoxicillin and a proton pump inhibitor (Biradar et al., 2008). Eradication 
of the organism has been shown to result in ulcer healing, prevention of peptic ulcer 
recurrence and may also reduce the prevalence of gastric cancer in high risk populations (Ali 
et al., 1991; Vaezi et al., 2000; Tanih et al., 2009).  However, resistance of the organism to 
antibiotics is a growing global concern which needs public health attention especially in 
developing countries. In Africa, an outsized amount of people die daily of avertable and 
treatable diseases because there is lack of basic health care. Even with the massive 
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development in health care made in the last half century, infectious diseases still account for 
25% of mortality globally and 45% in under-developed countries (Diallo and Zougran, 2008; 
Doughari and Manzara, 2008). Anti-infective drugs are crucially imperative in reducing the 
worldwide burden of infectious diseases.  
Medicinal plants are sources of enormous quantity of chemical substances which are able to 
initiate biological activities. These phytochemicals can enhance the treatment of human 
diseases. For example; the active principles of many drugs obtained from plants are 
secondary metabolites (Kubmarawa et al., 2007). Therefore, basic phytochemical 
investigation of plant extracts for their major phytoconstituents is vital. Different solvent 
extracts of plants have different phytochemical properties (Hassan et al., 2007). Many 
naturally occurring compounds found in medicinal plant extracts have also been shown to 
posses antimicrobial activities that inhibit the growth of microorganisms (Katsvana and 
Chigwaza, 2004; Ndip et al., 2008). 
Scientific investigations of medicinal plants used in folk medicine have attracted increased 
attention in the medical world, in a bid of finding solutions to the problems of multiple 
resistances to the existing synthetic antimicrobials. Most of the synthetic antibiotics now 
available in the market have major setback due to the accompanying side effects on the 
patients and resistance developed by the pathogenic microorganisms against these drugs. 
Thus, there is a need to search for new and more potent antimicrobial compounds of natural 
origin, especially from plants to overcome this problem. 
Lippia javanica is widely distributed throughout South Africa where it is used extensively in 
traditional herbal preparations, and commonly used as a decongestant for colds and coughs as 
well as diarrhoea (Viljoen et al., 2005). Its use has excelled in the treatment of respiratory 
aliments traditionally, which may either be fungal or bacterial as well as the treatment of 
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Gram-negative and yeast borne respiratory ailments (Viljoen et al., 2005).  However, some 
studies have shown that acetone and chloroform extracts of L. javanica are not active against 
E. coli and other bacteria (Samie et al., 2005). The acetone and methanol extracts of L. 
javanica were found to be active against most bacteria including S. aureus, B. subtilis, P. 
mirabilis and S. marcescens (Samie et al., 2005). Thus, the present study sought to evaluate 
the antimicrobial activity of L. javanica in a bid to identify active compounds of the plant that 
could be a source of potent antimicrobials. 
 PROBLEM STATEMENT 
Several studies have related a high prevalence of H. pylori to low-economic status, a situation 
common in the Eastern Cape Province in particular and other areas of the country in general. 
In fact, H. pylori infections have been shown to have a high prevalence in South Africa, 
being present in both asymptomatic and symptomatic individuals, as expected in developing 
countries (Pelser et al., 1997; Mosane et al., 2004; Samie et al., 2006; Dube et al., 2009).  
H. pylori infection is treated with potent combination therapies; a proton pump inhibitor and 
two antibiotics. These have a success rate of 80-90%, but problems including high levels of 
antibiotic resistance, undesirable side effects, poor patient compliance, are associated with 
significant levels of treatment failure and contraindications for some patients. In addition, the 
cost of combination therapy is also high. Some of these antibiotics are at times not readily 
available in rural areas thus compounding the problem of patients. Studies on anti-H. pylori 
activity of medicinal plants are lacking in South Africa. To the best of our knowledge, the 
plants has not been evaluated for its antimicrobial activity on clinical isolates of H. pylori 
circulating in South Africa, especially so when these organisms are known to exhibit 
profound heterogeneity.  
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HYPOTHESIS 
Extracts if L. javanica can provide potent and affordable antibacterial agents for the treatment 
of H. pylori. 
 
OVERALL OBJECTIVE 
 To assess the antimicrobial potential of extracts of Lippia javanica against H. pylori 
Specific objectives  
The specific objectives of this study are to:  
1. Screen the plant acetone, chloroform, ethanol, methanol, ethyl-acetate or water 
extracts for anti-H. pylori activity. 
2. Determine the minimum inhibitory concentration. 
3. Determine the rate of kill. 
4. Identify potential active compounds in the extracts. 
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CHAPTER TWO 
       LITERATURE REVIEW 
2.1 Introduction 
In developing countries a number of people die on a daily basis due to preventable and 
curable infectious diseases because there is lack of basic health care and financial support 
(Mulu et al., 2005). Although there is substantial management of infections in developing 
countries, infectious diseases still account for more than 13 million deaths per year globally 
and are continuing to be the major concern in health institutions. One in every two deaths in 
developing countries is caused by infectious diseases (Diallo and Zougran, 2008; Doughari 
and Manzara, 2008). However, for centuries bacteria have been known to colonise the 
stomach, yet known to be contaminants digested with food in patients presenting with gastric 
and stomach ulcers (Warren and Marshal, 1983; Bizzozero, 1983; Williamson, 2001). 
 Nonetheless, scientists continued to investigate Camphylobacter pyloridis, being difficult to 
culture. Warren and Marshall (1983), came up with a conclusive suggestion after successfully 
isolated and cultured the spiral species; that most of the stomach ulcers and gastritis caused 
by infection were due to a bacterium which was later known as H. pylori (Warren and 
Marshal, 1983). Self-ingestion experiments performed by Marshall (Marshall et al., 1985) 
and later on volunteers (Morris et al., 1991) demonstrated that these bacteria can colonize the 
human stomach, thereby inducing inflammation of the gastric mucosa (Blaser and Atherton, 
2004). These findings suggest that H. pylori has its primary reservoir in the stomach of 
humans and animals. 
After self-ingestion, Marshal developed symptoms that were associated with persistent 
gastritis, this was determined after sequential therapy with antibiotics including doxycycline 
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and bismuth subsalicyclate. However, this data inspired further investigation which 
documented that gastric colonization with H. pylori can lead to various upper gastrointestinal 
disorders namely: peptic ulcer disease, gastric cancer, chronic gastritis, and gastric mucosa-
associated lymphoid tissue (MALT) lymphoma. Robin Warren and Barry Marshal were 
awarded the 2005 Nobel Prize in Physiology/Medicine for the discovery of H. pylori and its 
effects on gastritis and peptic ulcer disease. According to the findings by Marshal and 
Warren, this brought an insight to the major clinical impact considering the management of 
infectious diseases and persistence of this pathogen in an environment which for some time 
was thought to be sterile and marks within reach the pathogenesis of chronic diseases. 
In 1886, Thoedor Escherish was the first to observe Helicobacter in the colons of infants later 
known as Campylobacter. In 1972, Sebalt and Veron isolated the bacteria from human feaces 
and called it ―vibrio like organism‖ and gave the name Campylobacter as genera based on 
shape and biological character (Samie et al., 2006). The organism is known for its helical or 
rod shape, microaerophilic, Gram negative, flagellated (2-6 flagella) bacterium, 2-4µm long 
with a diameter of 0.5µm; it is a slow growing organism with a low DNA composition and 
non fermentative metabolism (Fritz et al., 2006). 
A growing interest on Helicobacter has been noted due to an increase of peer-reviewed 
publications over the past few years. Studies have shown the bacteria‘s morphology, 
decreasing prevalence in the Western world, and other important facts about H. pylori 
although its transmission route is still poorly understood. H. pylori is still known to be 
prevalent in underdeveloped than in developed countries. A number of diagnostic tests can be 
performed to detect H. pylori infection, and can be optimally treated with antibiotics. 
Antimicrobial chemotherapy (a combination therapy) used for the management of H. pylori 
infections appears to be the most significant way to eradicate these infections. Nonetheless, 
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antimicrobial therapy is loaded with a number of innate boundaries such as resistance, cost of 
treatment, unavailability of drugs in rural areas and undesirable side effects. These and other 
factors necessitate a need to search for an alternative approach from natural sources such as 
plants for reduction of the global burden of infectious diseases (Mulu et al., 2004). These 
findings can shed light to efficient, large-scale, low cost and alternative solutions with less 
side effects to eradicate H. pylori infections. 
 
2.2 Morphology 
H. pylori is a pleomorphic, microaerophillic spiral Gram-negative motile rod bacterium 
which has been recognised as the causative factor of peptic ulcer disease, and an etiologic 
agent in the development of gastric cancer (Hoffman et al., 2004; Yang et al., 2005; Tiwari et 
al., 2005; Njume et al., 2009). H. pylori exhibits four to six unipolar sheathed flagella, which 
has led the bacterium to be adapted to live and survive in an acid environment (Kusters et al., 
2006) of the stomach in humans resulting in diseases or infections (Modena et al., 2007). 
However, the organism lacks fimbrial adhesions, differentiating the bacterium from other 
pathogens of the gastrointestinal tract. Nonetheless, the flagella confer mortility, thus allows 
rapid movement in viscous solutions including mucus layer found in the gastric epithelial 
cells (O‘toole et al., 2000). 
 
H. pylori possess five major outer membrane protein (OMP) families (Kusters et al., 2006).  
The largest family includes putative adhesins. The other four families include porins, iron 
transporters, flagellum-associated proteins and proteins of unknown function. Like other 
typical Gram-negative bacterium, the outer membrane of H. pylori consists of phospholipids 
and lipopolysaccharide (LPS). The O antigen of LPS may be fucosylated and mimic Lewis 
blood group antigens found on the gastric epithelium (Sherif et al., 2004; Kusters et al., 
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2006). The outer membrane also contains cholesterol glucosides, which are found in few 
other bacteria (Kusters et al., 2006). Gram-negative bacteria including H. pylori, and 
mycobacteria both possess thick outer membranes that are highly hydrophobic, providing 
these organisms with a permeability barrier especially towards hydrophilic compounds such 
as macrolide antibiotics like erythromycin. This in part explains the greater resistance 
observed by Gram-negative bacteria as opposed to Gram-positive organisms (Cooper et al., 
2002; Starvi et al., 2007).  
 
2.3 Pathogenisis and clinical manifestation 
H. pylori cells characteristically attach to surface mucous cells and colonize the mucous gel 
layer covering the gastric mucosa. H. pylori infection increases proliferation activity of 
gastric epithelial cells without adhering to the proliferating epithelial cells which are localised 
around the neck of the normal gastric mucosa (Masayoshi et al., 2005). H. pylori infection is 
probably one of the most common bacterial infections worldwide (Sherif et al., 2004; Tiwari 
et al., 2005). The organism has also been documented as one of the most genetically diverse 
bacterial species and its infection persists for life with inflammation of the gastric mucosa 
leading to a wide variety of upper gastrointestinal tract diseases such as atrophic gastritis, 
gastric/duodenal ulcer, gastric cancer, gastric MALT lymphoma, and hyper-plasmic gastric 
polyps (Tanih et al., 2010; Asaka et al., 2010).  Approximately 20% of persons infected with 
H. pylori develop related disorders during their life time (Hoffman et al., 2004).  Irrespective 
of their histology, most gastric cancers arise from mucosa infected H. pylori, and these 
tumours vary rarely arise from gastric mucosa without inflammation which therefore, makes 
H. pylori to be considered as the contributing factor that is strongly related to the 
development of gastric cancer (Asaka et al., 2010). 
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2.3.1 Gastritis  
H. pylori is genetically versatile, diverse and adapt readily to stress conditions such as gastric 
acid (Konturek et al., 2000). Their ability to adhere, invade, evade host defences and cause 
tissue damage, is prominently due to their production of colonization and virulence factors. 
The bacterium has flagella and moves through the stomach lumen and drills into the mucoid 
lining of the stomach (Scheiman and Cutler, 1999; Ottemann and Lowenthal, 2002; Michael 
and John, 2006). Many bacteria can be found deep in the mucus, which is continuously 
secreted by mucous cells and removed on the luminal side. To avoid being carried into the 
lumen, H. pylori senses the pH gradient within the mucus layer by chemotaxis and swims 
away from the acidic contents of the lumen towards the more neutral pH environment of the 
epithelial cell surface (Falsafi et al., 2005; Asaka et al., 2010). 
It produces adhesins (Petersen and Krogfelt, 2003) which binds to membrane-associated 
lipids and carbohydrates that assists the bacterium to remain on epithelial cells. On the other 
hand, a huge amount of urease is produced which breaks down urea to carbon dioxide and 
ammonia that is converted into ammonium ion by absorbing hydrogen from water upon its 
breakdown into hydrogen and hydroxyl ions (Mobley et al., 1995; Ilver et al., 1998). The 
essential role of urease as a virulence factor is shown by the fact that urease-defective H. 
pylori mutants cannot colonize the stomach, thus the survival of H. pylori in the acidic 
environment is dependent on urease, and would eventually die without the enzyme (Smoot, 
1997; Nariman et al., 2004; Tanih et al., 2009). However, urea is toxic to the bacterium at 
neutral pH because a hostile alkaline environment is generated (McNamara and El-Omar, 2008).  
 
Colonization of the stomach by H. pylori results in chronic gastritis, resulting in an 
inflammation of the stomach lining. The severity of the inflammation is likely to underlie H. 
pylori-related diseases (Perez-Perez et al., 2000; Ndip et al., 2008; Dube et al., 2009). 
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Duodenal and stomach ulcers are mainly caused by an inflammation thus, allowing the acid 
and pepsin in the stomach lumen to engulf the mechanisms that safe guards the stomach and 
duodenal mucosa from these caustic substances. The type of ulcer that develops depends on 
the location of chronic gastritis, which occurs at the site of H. pylori colonization (Hoffman 
et al., 2004; Asaka et al., 2010). The acidity within the stomach lumen affects the 
colonization pattern of H. pylori and therefore ultimately determines whether a duodenal or 
gastric ulcer will form. In people producing large amounts of acid, H. pylori colonizes the 
antrum of the stomach to avoid the acid-secreting parietal cells located in the corpus of the 
stomach (Kato et al., 2007; Tanih et al., 2009).  
 
The inflammatory response to the bacteria induces G-cells in the antrum to secrete the 
hormone gastrin, which travels through the bloodstream to the corpus (Uemura et al., 2001; 
Nasu et al., 2005). Gastrin stimulates the parietal cells in the corpus to secrete even more acid 
into the stomach lumen. Chronically increased gastrin levels eventually cause the number of 
parietal cells to also increase, further escalating the amount of acid secreted (Hoffman et al., 
2004). The increased acid load damages the duodenum, and ulceration may eventually result. 
In contrast, gastric ulcers are often associated with normal or reduced gastric acid production, 
suggesting that the mechanisms that protect the gastric mucosa are defective (Boyanova et 
al., 2000). In these patients, H. pylori can also colonize the corpus of the stomach, where the 
acid-secreting parietal cells are located. However chronic inflammation induced by the 
bacteria causes further reduction of acid production and, eventually, atrophy of the stomach 
lining, which may lead to gastric ulcer and increases the risk for stomach cancer (Asaka et 
al., 2010). 
 
2.3.2 Gastric cancer 
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Sero-invasion rates ranging from 5%-10% in infected persons with H. pylori have been 
reported to be spontaneous as the majority of individuals remain asymptomatic (Lacy et al., 
2001; Wong et al., 2004).  The progression of atrophic gastritis in infected patients often 
begins with chronic superficial gastritis to cause disease. This may be due to development of 
gastric carcinoma resulting from the cellular cascade. In patients with severe, multifocal 
atrophic gastritis, the data shows a 90-fold increase in rates of gastric carcinoma (Occhialini 
et al., 2000; Hoffman et al., 2004; Fukase et al., 2008). The formation of the tumour involves 
DNA damage induced by different cytokines and free radicals released in the setting of 
chronic inflammation in susceptible persons (Kato et al., 2005; Nasu et al., 2005; McClain et 
al., 2009).  
H. pylori is linked with the progression and development of adenocarcinoma of the antrum 
and body of the stomach including: gastric mucosa associated lymphoid tissue lymphomas 
(MALT) (Parkinson et al., 2000; Hoffman et al., 2004; Masayoshi et al., 2005; Argent et al., 
2008). On the other hand, the organism stimulates lymphocytic infiltration of the mucosal 
stroma which acts as a focus for cellular alteration and proliferation, eventually resulting in 
neoplastic alteration to lymphoma (Fukase et al., 2008).  According to Morgner et al. (2000), 
it has been documented that deterioration of low-grade gastric MALT lymphoma can be 
accomplished in 70% to 90% of patients with eradication of H. pylori infection.  An 
ultrasound endoscopic investigation revealed an invaluable grade of MALT lymphoma and 
predicted the effectiveness of treating H. pylori infection to acquire regression of the 
lymphoma (Argent et al., 2008). 
 
2.3.3 Peptic ulcer 
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Previous studies have shown that H. pylori is the causative agent of peptic ulcers found 
mostly in the human stomach worldwide.  Eradicating the infection can alter the natural 
course of peptic ulcer disease by dramatically reducing its recurrence rate in treated patients, 
compared with untreated patients (Van der Hulst et al., 1997; Williamson et al., 2001; Njume 
et al., 2009). Elimination of the bacteria occurs in patients with duodenal and gastric ulcers 
who have no history of nonsteroidal anti-inflammatory drug use. Eradication of H. pylori 
slows down the progression of gastric cancer but re-occurrence may occur at site different 
from the resection site (Asaka et al., 2010) However, the mechanism by which H. pylori 
induces peptic ulcer disease is moderately implicit but most probable entails a combination of 
genetic intolerance of the host, virulence factors of the organism (eg, VacA and CagA 
proteins), mechanical damage to the mucosa, and modification of gastric and duodenal 
secretions (Albert et al., 2005; Tanih et al., 2009). 
 
2.3.4 Non-ulcer Dyspepsia 
Non-ulcer dyspepsia encompasses a collection of diverse symptoms including: dysmotiliy, 
ulcer, and reflux-like symptoms. Studies have revealed that non-ulcer dyspepsia is caused by 
a number of factors like altered visceral sensation, way of life, stress, altered visceral 
sensation, alterations in gastric acid secretion, gastric clearance and increased serotonin 
sensitivity, as well as H. pylori infection (Tanih et al., 2009; Asaka et al., 2010). Olden and 
Drossman (2000) in their review highlighted the role played by psychosocial impairment in 
patients with non-ulcer dyspepsia. On the other hand, studies also showed a link between H. 
pylori infection and non-ulcer dyspepsia; thus patients with the latter condition were twice as 
likely to be positive for the organism (Vaira et al., 2000). Nonetheless, regardless of 
epidemiologic confirmation, treatment studies have failed to consistently confirm that 
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eradication of H. pylori results in enhancement of non-ulcer dyspepsia symptoms (Hoffman 
et al., 2004; Lee et al., 2008). Therefore, suppression of the organism cannot be considered 
the standard of care in all patients with non-ulcer dyspepsia, because H. pylori infection is 
only a single part of the mutifactorial etiology of the disease. 
 
2.3.5 Gastroesophageal Reflux Disease (GERD) 
A lot of interest has been focused on the feasible connection between infection with H. pylori 
and gastroesophageal reflux disease (GERD) in its diverse manifestations (eg, esophagitis, 
Barrett‘s esophagus). Various researchers have recommended an association between the 
existence of H. pylori and reduced threats for developing esophagitis and Barrett‘s esophagus 
(Loffeld et al., 2000; Willian et al., 2004; Biradar et al., 2008); even though this opposite 
relationship is maintained/ sustained by various prevalence studies, whilst others failed to 
verify it (Dube et al., 2009; Tanih et al., 2009; Asaka et al., 2010). Investigations have also 
specified that certain strains of H. pylori, particularly the CagA positive strains, may be 
protective against the development of Barrett‘s esophagus (Vaezi et al., 2000; Tanih et al., 
2009). In addition, Labenz and colleagues revealed that the frequency of esophagitis may, in 
fact, increase after eradication of the organism (Labenz et al., 1997). 
H. pylori treatment can lead to exacerbation of GERD in several patients, prompting many 
gastroenterologists to suspend endoscopic antral biopsies in patients with significant GERD 
and absence of ulcer (Labenz et al., 1997; Parsons et al., 2001). Conversely, other studies 
using endoscopic findings, pH probe measurements, and histology to determine the presence 
of H. pylori did not find any association between GERD and infection with H. pylori (Oberg 
et al., 1999; Graham and Shiotani, 2005). 
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2.3.6 Virulence proteins  
The genome of H. pylori is about 1.7 Mbp, with a G+C content of 35 to 40%. Several strains 
of H. pylori have been identified, including: H. pylori strain 26695 with 1,587 genes, and J99 
strain with 1,491 genes (Tomb et al., 1997; Baltrus et al., 2009). Two copies of 16S, 23S, and 
5S rRNA genes are contained in both genes, whereas various strains carry one or more 
cryptic plasmids, that do not carry antibiotic resistance or virulence factors/genes (Albert et 
al., 2008; Baghaei et al., 2009). At some instance most of these plasmids outlines the 
foundation of H. pylori, E. coli shuttle vectors used in molecular cloning experiments 
(Baghaei et al., 2009). Detailed characterisation of H. pylori is lacking, though the existence 
of H. pylori-infecting bacteriophages has been well documented (Masayoshi et al., 2005). 
 
The majority of the H. pylori-infected individuals world-wide are either asymptomatic or 
only have gastritis, associated with epigastric pain, abdominal distention or bloating, 
belching, nausea, flatulence, and halitosis (Meurer and Bower, 2002; Ndip et al., 2008). 
Disease outcome may be the result of a number of factors including host factors, 
environmental factors and differences in the prevalence or expression of bacterial virulence 
elements (Ahmad et al., 2009). Most of the clinical isolates of H. pylori from patients 
suffering from peptic ulcer or malignant disease express virulence-associated factors 
including: urease, the vacuolating cytotoxin VacA, as well as the cytotoxin-associated geneA 
antigen CagA (Asahi et al., 2000; Mukhopadhyay et al., 2008). Although these virulence 
factors have been proposed, the best studied virulence factor is the cag pathogenicity island 
(PAI) which is an approximately 40 kilobase pair region (Asahi et al., 2000; Baghaei et al., 
2009; Tanih et al., 2010).  
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The cag PAI encodes a type IV secretion system, where CagA is delivered into host cells. 
After the delivery into gastric epithelial cells, CagA is mainly tyrosine-phosphorylated at 
Glu-Pro-Ile-Tyr-Ala (EPIYA) motifs located in the 3‘ region of cagA gene (Masayoshi at al., 
2005; Argent et al., 2008; Baghaei et al., 2009). It also causes inflammation by activating the 
NF-kB and secretion of cytokines and chemokines such as interleukin 8 (IL-8), and facilitates 
the translocation of CagA into the cytosol of epithelial cells, where it becomes tyrosine 
phosphorylated by Src kinases. Phosphorylated CagA interacts with SHP-2 phosphatase 
(Higashi et al., 2002; Figueroa et al., 2002; Hocker et al., 2003; Ko et al., 2008) and results 
in the formation of long needle like cellular protrusions referred to as the ‗hummingbird‘ 
phenotype. This phenotype is considered to be proliferative, so may be important in 
carcinogenesis (Argent et al., 2008), hence H. pylori has been recognized as a class I 
carcinogen. 
 
2.4. LABORATORY DIAGNOSIS OF H. PYLORI 
The significant burden of H. pylori-related sequelae indicates that there is a need for the exact 
diagnosis of the infection (Nakamura et al., 2001; Nguyen et al., 2009) with advantages and 
limitations. Numerous invasive and non- invasive diagnostic tests are accessible for 
determining the presence of H. pylori infections. Invasive tests require endoscopy and these 
include; the biopsy urease test, histology, fluorescent in situ hybridization, culture and 
polymerase chain reaction (PCR), whilst non- invasive tests are more convenient and do not 
require endoscopy. These include; 
13
C-urea breath tests, serology and stool antigen enzyme 
immunoassay tests (faeces, dental plaque) (Gramley et al., 1999; Bravos et al., 2003; Tanih et 
al., 2008). 
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2.4. 1 Histology  
Histology has been traditionally used to diagnose the presence of bacteria or H. pylori 
infection as well as any type of infection present in a specimen. A need for an endoscopy to 
obtain a tissue disadvantages this technique. However, limitations arises at times because of 
an insufficient amount/number of biopsy specimens obtained or failure to obtain specimens 
from different areas of the stomach (Choe et al., 2001). On the other hand, many stains can 
be used to detect H. pylori including: Warthine-Starry, Hp silver stain, Dieterle, Giemsa, 
Giminez, acridine orange, McMullen and immunostaining (Gatta et al., 2003; Ndip et 
al.,2004); these involve longer processing times and higher costs. Normally the stains used 
for the evaluation of inflammatory cells are haematoxylin and eosin as well as Giemsa stain 
which is used to detect H. pylori because of its simplicity, low cost and technical simplicity 
(Gatta et al., 2003). However, histologic sampling does allow for definitive diagnosis of 
infection, as well as of the degree of inflammation or metaplasia and the presence/absence of 
MALT lymphoma or other gastric cancers in high-risk patients. 
 
2.4.1.2 Culture 
Helicobacter pylori can be cultured from gastric biopsies (Kel et al., 2002; Lopez-Vidal et 
al., 2008). However, H. pylori  is a fragile organism. It must be protected from desiccation 
and contact with oxygen and room temperature. It is mandatory not to expose the biopsy 
specimens to air and to place them either in a saline solution for short-term transport (4 h 
maximum) or in a transport medium, usually consisting of semisolid agar, maintained at 4°C. 
Therefore, the biopsies specimens are kept in a transport medium (Stuart‘s transport medium) 
for 24 h at 4 
0
C, then cultured on agar (Columbia or brainheart infusion), generally with 
added antibiotics and albumin. The agar plates are incubated in a micro-aerobic environment, 
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using a jar with a gas-generating kit for a micro-aerobic atmosphere (5% oxygen and 5-10% 
CO2) and incubated for at least 5 days at 37 
0
C. The growth may start to appear after 3 days 
(Yang and Seo, 2005). The organisms are identified as H. pylori when they form 
characteristic visible colonies which show typical cell morphology on Gram staining and 
biochemical tests (Yang and Seo, 2005; Salehi et al., 2008). The colonies are Gram negative, 
urease, oxidase, and catalase positive. The disadvantage about culture is that the organism is 
fragile out of the gastric environment and yet inexpensive (Kel et al., 2002; Yang and Seo, 
2005). Therefore, the role of culture in diagnosis of the infection is limited mostly to research 
and epidemiologic considerations. 
 
2.4.1.3 Rapid urease test 
The test is based on the activity of the H. pylori urease enzyme, which splits urea to form 
ammonia. Ammonia enhances pH, which is identified by the indicator phenol red (Molbey et 
al., 1988). Various urease tests are commercially accessible, together with gel-based 
(CLOtest, HpFast), paper-based (PyloriTek, ProntoDry HpOne) and liquid-based tests 
(CPtest, EndoscHp). Results are obtaibed within 24 hours, depending on the format of the test 
and number of Helicobacter in the biopsy specimen (Kaklikka et al., 2006).  This test is 
advantageous in the sense that it is cheap, rapid, and extensively accessible.  Limitations 
maybe due to false positive results; decreased urease activity, caused either by current intake 
of antibiotic agents, bismuth compounds, proton pump inhibitors, or sucralfate or by bile 
reflux, can contribute to these false-positive results (Midolo et al., 1999), as well as the 
increased luminal pH which can lead to extremely high pH adjacent to the organism, such 
that the organism can be destroyed by the action of its own urease (Kaklikka et al., 2006).  
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2.4.1.4 Polymerase Chain Reaction  
The polymerase chain reaction (PCR) has increasingly been described as the latest gold 
standard for detecting some microbes. PCR is the most commonly used nucleic acid 
amplification technique for the diagnosis of infectious disease, surpassing the probe and 
signal amplification methods with marked sensitivity and specificity (Frenck et al., 2006). It 
allows identification of the organism in small samples with few bacteria present and entails 
no special requirements in processing and transport. Moreover, PCR can be performed 
rapidly and cost- effectively, and it can be used to identify different strains of bacteria for 
pathogenic and epidemiologic studies. PCR has been used extensively for the diagnosis of H. 
pylori infection from gastric biopsy specimens, saliva, faeces and archived specimens 
(Bravos et al., 2003; Tiwari et al., 2005; Dube et al., 2009; Tanih et al., 2009).  
This technique has been used successfully to detect H. pylori DNA in gastric tissues by 
amplifying genes such as the adhesin genes, the urease gene and the 16S rRNA gene (Tiwari 
et al., 2005). The 16S rRNA gene of H. pylori is a highly specific target for amplification and 
has been used previously to help reclassify the organism. The 16S rRNA is one of the 
specific targets to confirm H. pylori infection, and positive amplification of H. pylori specific 
DNA may be considered as a direct evidence of the presence of the pathogen. PCR yields 
information on the presence of potential virulence markers in the strain (Vaira et al., 2000), 
which might have implications for the development of severe disease or efficacy of 
eradication (Bravo et al., 2003). Different primers have been utilised and some have been 
developed into commercial kits. Different loci have been used as target for amplification: 16S 
rRNA; A-, B- and C-urease; flaA; cagA; vacA and heat-shock protein (hsp). Real-time PCR 
results can be obtained using light-cycle technology (Ricci et al., 2007).   
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It also requires special laboratory conditions with separate facilities. In addition, because 
PCR can detect segments of H. pylori DNA in the gastric mucosa of previously treated 
patients, false-positive results can occur, and errors in human interpretation of bands on 
electrophoretic gels can likewise lead to false-negative results (Ko et al., 2008; McClain et 
al., 2009; Tanih et al., 2009). 
 
2.4.1.5 Urea Breath Test 
Urea breath test correspondingly relies on the urease activity of H. pylori to detect the 
presence of active infection. Patients with suspected infection ingest either 
14
C- labeled or 
13
C- labeled urea. The 
13
C- labeled urea has an advantage of being nonradioactive and thus 
theoretically safe for children and women of childbearing age. Urease, if present, splits the 
urea into ammonia and isotope-labeled carbon dioxide; the carbon dioxide is absorbed and 
eventually expired in the breath, where it is detected. Besides being excellent for 
documenting active infection, this test is also valuable for establishing the absence of 
infection after treatment, an important consideration in patients with a history of complicated 
ulcer disease with bleeding or perforation (Gatta et al., 2003). In addition, a urea breath test is 
relatively inexpensive (whichever isotope is used), is easy to perform, and does not require 
endoscopy. However, if the patient has recently ingested proton pump inhibitors, antibiotic 
agents, or bismuth compounds, a urea breath test can be of limited value. Therefore, at least 1 
week should separate the discontinuing of antisecretory medications and testing for active 
infection (Frenck et al., 2006; Njume et al., 2009), and 4 weeks should separate treatment of 
H. pylori infection and testing for eradication of the organism. Moreover, except for major 
medical centers or tertiary referral centers where results are usually available in fewer than 24 
hours, a urea breath test may be further limited by a turn around time of several days (or 
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longer) required for transport of samples and analysis by specialized laboratories not present 
in many community settings. 
 
2.4.1.6 Serologic Tests 
The test is used for diagnosis of antigen infection and antibodies can be detected long after a 
successful treatment. The most widely used test in the assay uses polyclonal anti-H. pylori-
capture antibodies absorbed to microcells (Ricci et al., 2007). These antibodies can be 
detected in serum or whole-blood samples. The presence of IgG antibodies to H. pylori can 
be detected by use of a biochemical assay commercially available. The test is highly specific 
and sensitive like the urea breath test (Tanih et al., 2009). However, this method is not a 
useful means of confirming eradication of H. pylori; several different samples and changes in 
titers of specified amounts over time would be needed (Lerang et al., 1998). In addition, few 
patients become truly seronegative, even after eradication of the organism (Momoyo et al., 
2006). In low-prevalence populations, serologic tests should be a second-line methodology 
because of low positive predictive value and a tendency toward false-positive results. 
Serologic tests may be useful in identifying certain strains of more virulent H. pylori by 
detecting antibodies to virulence factors associated with more severe disease and complicated 
ulcers, gastric cancer, and lymphoma. 
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2.4.1.7 Stool antigen testing 
Stool antigen testing uses an enzyme immunoassay to detect the presence of H. pylori antigen 
in stool specimens. A cost effective and reliable means of diagnosing active infection and 
confirming cure, such testing has a sensitivity and specificity comparable to those of other 
noninvasive tests (Monteiro et al., 2001; Ndip et al., 2004; Frenck et al., 2006; Ricci et al., 
2007; Dube et al., 2009). Questions remain regarding possible cross reactivity with other 
Helicobacter species present in the intestines, but definitive studies are lacking. 
 
2.5 EPIDEMIOLOGY 
2.5.1 Prevalence 
H. pylori infection is probably one of the most common bacterial infections worldwide 
(Sherif et al., 2004; Falsafi et al., 2005; Tiwari et al., 2005). It is responsible for a significant 
cause of morbidity and mortality imposing a major burden on health care systems worldwide. 
The prevalence of H. pylori infection varies from 20-50% in industrialized countries to over 
80% in developing countries (Feldman, 2001; Ndip et al., 2004). 
The organism has been reported to be prevalent in South Africa. For example, Pelser et al. 
(1997) documented a high prevalence of H. pylori antibodies (67-84%) in children in 
Bloemfontein, while Mosane et al. (2004) also documented H. pylori IgG antibodies in South 
African mothers and their children. Recently, Samie et al. (2006) reported an H. pylori 
prevalence of 50.6% in a study in Venda, North of South Africa. H. pylori prevalence‘s of 
84%, 83%, 70%, and 50.6% have been respectively reported in Gauteng, Mpumalanga, 
Western Cape, and Limpopo Provinces of South Africa(Fritz et al., 2006). Childhood appears 
to be the critical period during which H.  pylori is acquired, especially in areas of 
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overcrowding and socio-economic deprivation (Feldman, 2001; Horiuch et al., 2001; Ndip et 
al., 2004; Dube et al., 2009). 
As prevalence in developing countries remains moderately stable, it is constantly declining in 
developed countries (Ndip et al., 2004; Asrat et al., 2004 Salehi et al., 2008). However, 
improved hygiene, sanitation and activation of carriership via antimicrobial treatment may be 
the contributing factor to the reduction of the infection in children. Studies show that in 
developing countries infections due to H. pylori are still persistent in the first 5 years of 
childhood (Fegueiredo et al., 2002; Ndip et al., 2004; Kandulski et al., 2008; Reyberg et al., 
2008) and increases with age in under-developed countries. This increase results only to a 
small extent from H. pylori acquisition at later age. H. pylori infection appears to be less than 
0.5% in adults in the Western world and higher prevalence of infection among the elderly has 
been noted, thus reflecting a birth cohort effect with higher infection rates in the past ( 
Kaklikkaya et al., 2006; Parsonnet et al., 2009). Eradication of H. pylori from the population 
and improved hygiene and housing conditions have resulted in a lower infection rate in 
children, which is reflected in the age distribution of this lifelong-colonizing bacterium 
(Salehi et al., 2008; Dube et al., 2009; Torres et al., 2009). Generally, new-fangled infections 
usually arise within childhood and endure for life not unless treated. 
 
2.5.2 Transmission of H. pylori infection 
In Africa, H. pylori infection in early life is strongly associated with pernicious anaemia, 
growth faltering and increased susceptibility to other food and waterborne pathogens, 
especially in young children from the poorest societal strata (Argent et al., 2008). H. pylori 
transmission remains poorly understood, however it is believed to spread from person to 
person through oral-to-oral or faecal-to-oral routes (Thomas et al., 2004; Ahmadu et al., 
2007; Dube et al., 2009). In children, gastric inflammation could cause low gastric secretion 
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which results in impaired ―gastric barrier‖ associated with increased susceptibility to enteric 
infections, a major public health concern linked to diarrhoea, malnutrition and growth failure 
in developing countries (Thomas et al., 2004; Hoffman et al., 2004; Tanih et al., 2009).  
Acquisition of H. pylori in children is believed to be related to close family members (Van 
der Ende et al., 1996; Raymond et al., 2004; Alborzia et al., 2006; Rowland et al., 2006; Ko 
et al., 2008). Such observations suggest that these infections may be associated with low 
socioeconomic status and overcrowded living conditions (Delport et al., 2006). H. pylori has 
been detected in saliva, vomitus, gastric refluxate, and faeces (Ferguson et al., 2001; 
Parsonnet et al, 1997;Sugiyamea et al., 1998; Sharara et al., 2002;  Ricci et al., 2007), but 
there is lack of convincing evidence for the principal transmission route.  
The existence of H. pylori DNA in environmental water sources, probably reflects 
contamination with either naked DNA or dead H. pylori organisms (Dube et al., 2009). Li et 
al. (2002) successfully cultured H. pylori from wastewater that represented faecal 
contamination of water. Hence, an increased faecal contaminants is sustained by the 
occurrence of H. pylori infections among institutionalized young people during outbreaks of 
gastroenteritis (Lopez-Vidal et al., 2008; Dube et al., 2009).  
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2.5.3 Treatment of Helicobacter pylori 
Antibiotic resistance is a major cause of treatment failure. H. pylori infection is often treated 
with a triple therapy, such as metronidazole, clarithromycin, amoxicillin and a proton pump 
inhibitor (PPI) (Alarcon et al., 2001; Al-Qurahi et al., 2001; Kato et al., 2002; Sharara et al., 
2002; Asaka et al., 2010).  Eradication therapy of symptomatic H. pylori infection 
substantially reduces the recurrence of associated gastro-duodenal diseases. Therapy entails 
complicated regimens of several antimicrobial agents for at least two weeks.  In general, the 
triple therapy regimens entail two of the following antibiotics: metronidazole, clarithromycin, 
amoxicillin and tetracycline with a proton pump inhibitor or bismuth (Hoffman et al., 2004; 
Duck et al., 2004; Njume et al., 2009).  
Combination therapy may have a success rate of 80-90%, but can be the cause of undesirable 
side effects including: vomiting, epigastric pain, abdominal discomfort and poor patient 
compliance (Bina et al., 2000; Njume et al., 2009);   all these factors are associated with the 
major high levels of treatment failure. The most common cause of treatment failure are 
patient noncompliance and antimicrobial resistance of the infecting H. pylori strain. 
Quadruple regimens are used as a salvage therapy when triple therapy regimens have failed. 
Pre-treatment resistance of the organism has been reported to compromise the efficacy of 
treatment (Gatta et al., 2001; Adrienne et al., 2007; Asaka et al., 2010). Other treatment 
regimens can be a 7-days treatment with a double dose of PPI plus clarithromycin and 
metronidazole, or a double dose of PPI plus amoxicillin and metronidazole (Boyanova et al., 
2009; Njume et al., 2009). According to studies in the literature, there is evidence revealing 
that natural antimicrobials can act as resistant microbial inhibitors (Okunade et al., 2002; 
Adebolu, 2005; Aboderin et al., 2007; Baghaei et al., 2009). There is an increased need for 
the identification of new antimicrobials that are capable of inhibiting and treating a wide 
range of microorganisms including multi-drug resistant strains of bacteria. 
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The emerging and hasty spread of bacteria conveying multidrug resistance (MDR) has called 
for the invention of new antimicrobials and resistance-modifying agents, particularly in 
nosocomial situations (Ngemenya et al., 2006). For these microorganisms to resist the lethal 
effects of environmental toxins, they have devised a diverse system for resistance including 
that of natural antimicrobial agents, of which some have been developed into anti-fungal 
drugs (Gblade et al., 1999; Perron et al., 2005; Fernandez et al., 2008; Truong-Bolduc et al., 
2005). For this reason, there is one way or an initial step to stop these toxic compounds, that 
is, by actively reducing their entry into the cells through the action of efflux pumps located in 
the cytoplasmic membrane (Truong-Bolduc et al., 2005). 
 
2.6 Prevention 
H. pylori is a major cause of diseases of the upper gastrointestinal tract. Hence, an 
understanding of the route of H. pylori transmission is important if public health measures to 
prevent its spread are to be implemented. Researchers are studying different adjuvants, 
antigens, and routes of immunization to ascertain the most appropriate system of immune 
protection, with most of the research only recently moving from animal to human trials 
(Alborzia et al., 2006; Kabir, 2007). Improved home sanitation, decreasing family size, less 
household crowding, changes in dietary habits, improvements in refrigeration and hygiene at 
home are beneficial.  
For gastric cancer, the unique opportunity is a preventive strategy against the disease 
(Graham and Shiotani, 2005). Eradication therapies are either used to reverse the inflamed 
mucosa to normal or to prevent further progression of advanced chronic changes (atrophic 
gastritis, intestinal metaplasia). Although H. pylori infection is a significant risk factor for the 
development of gastric cancer, there are few controlled clinical trials showing that eradication 
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can prevent the progression from normal gastric mucosa to gastric cancer (Smith et al., 
2007). 
The clinical usefulness of eradicating H. pylori requires further investigations as current 
regimens are expected to achieve greater than 85 to 90 percent rates of eradication after one 
to two weeks of treatment. Once treated, re-infection rates are less than 0.5 percent per year. 
Management of peptic ulcers in some patients may require maintenance treatment (Graham 
and Shiotani, 2005; Malfertheiner et al., 2008). 
 
2.7 Factors affecting H. pylori treatment. 
Some  of the factors known to induce treatment failure include drug expenses and 
accessibility, side effects (Alarcon et al.,1999), the need of infiltration of antibiotics into the 
depth of gastric mucosa (Wong et al., 2004), antibiotic inactivation by pH, and misuse of 
drugs by patients (Oderd et al., 2001; Bytzer and O‘Morain, 2005). The lack of correlation 
between in vitro susceptibility test and in vivo efficacy and the presence of H. pylori strains 
with primary or secondary resistance to the antimicrobial agents used (Bytzer and  O‘morain, 
2005), duration of treatment and antibiotics dosage (Njume et al., 2009) are also important. 
Antimicrobial resistance is escalating and regional deviations in susceptibility and resistance 
patterns maybe attributed to differences in local antibiotic prescriptions, antibiotic usage in 
the community and mass eradication programmes for H. pylori (Ndip et al., 2008). 
The recommended duration of therapy for H. pylori eradication is 10 to 14 days (Njume et 
al., 2009). Potential benefits for shorter regimens include: better compliance, fewer adverse 
drug effects, and reduced cost to the patient (Meurer and Bower, 2002; Fernandez et al., 
2008). Low gastric pH seems to affect the activity of antibiotics since most are active at 
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neutral pH. However, the effect that the gastrointestinal environment may have on these 
orally consumed extracts is usually not explored even though it is well-known and accepted 
in biopharmaceutics that the gastrointestinal system plays a considerable part in the ultimate 
bioavailability of conventional medicines (O‘Gara et al., 2000; Hassan et al., 2007). The 
human gastrointestinal tract transforms orally consumed substances into and waste products 
by means of a digestive process.  
The fluids present in the gastrointestinal system contain various substances and enzymes 
which aids in the digestion process. The stomach has a pH between 1 and 2 due to the 
secretion of hydrochloric acid and contains the digestive enzyme pepsin. The pH of the small 
intestine ranges between 5.1 and 7.5 and contains numerous digestive enzymes (Mader, 1996; 
Hassan et al., 2007). It is well documented that some active pharmaceutical ingredients have 
to be protected, e.g. through enteric coating, against this harsh environment in order to be 
effective.  
The presence of hydrochloric acid and enzymes in the stomach can easily cause acid or 
enzyme catalysed hydrolysis of orally consumed compounds thereby resulting in chemical 
modification and inactivation. Presystemic metabolism and degradation in the gastrointestinal 
tract primarily results in reducing the bioavailability of medicines. However, in the case of 
pro-drugs these processes are essential for the active parent drug to become available for 
absorption. Medicines such as erythromycin stearate depend on degradation in the 
gastrointestinal tract to release the therapeutically active parent molecule (Boargets et al., 
2006). It exhibits limited solubility in gastric fluid but dissolves and dissociates readily in the 
intestinal fluid, liberating the free base which is absorbed (Duck et al., 2004; Adeniyi et al., 
2009).  
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 It has been well documented that minimal bactericidal concentrations (MBC) and minimal 
inhibitory concentrations (MIC) of most active antibiotics against H. pylori excluding 
metronidazole and tetracycline, are dependent on the pH of the environment (Malfertheiner et 
al., 2007; Argent et al., 2008). At pH values lower than 7 or 7.4, the MIC increases. This is 
why PPI‘s are used in therapy so as to increase the pH of the stomach, to allow better 
antimicrobial activity (Alarcon et al., 1999; Choe et al., 2001). In patients who are acid hyper 
secretors, the pH remains low; consequently, antimicrobial activity may be insufficient to 
eradicate the bacteria. As a result, increasing the dosage of PPI in the treatment regimen may 
have beneficial effects (Malekzadeh et al., 2004). 
The most important causes of treatment failure are poor patient compliance and the 
development of bacterial resistance to antimicrobial agents (Ndip et al., 2007). Patient 
compliance can only be improved by choosing a simple and well tolerated treatment regimen 
(Steenkamp et al., 2007). In addition, patients should be educated on the importance of 
eradication therapy  
2.8  Medicinal plants 
Phytomedicine has shown great promise in the treatment of intractable infectious diseases. It 
is estimated that plant materials are present in or have provided the models for about 50% of 
synthesized drugs and herbal medicine continue to play a role in the cure of diseases. 
Traditional medical practitioners play important roles in health care delivery in Africa, 
including South Africa. These plants are ingested as decoctions, teas and juice preparations to 
treat respiratory infections (Clarkson et al., 2004; Birdar et al., 2008; Njume et al., 2009). 
They are also made into a poultice and applied directly on the infected wounds or burns. 
When people from these remote communities get an infectious disease, they are usually 
treated by traditional healers and ―shamans‖ because of their expertise in such procedures as 
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making diagnoses, treating wounds, setting bones and making herbal medicines (Mulu et al., 
2004; Hassan et al., 2007; Centikaya et al., 2008). 
Traditional healers claim that their medicine is cheaper and more effective than modern 
medicine. They claim that patients of these communities have a reduced risk to get infectious 
diseases from resistant pathogens than people from urban areas treated with traditional 
antibiotics because of the accessibility and affordability of medicinal plants. However, if they 
are treated in a hospital the chance of contracting a nosocomial infection is increased 
(Adjanohoun et al., 1996; Hassan et al., 2007; Temaru et al., 2007). One way to prevent 
antibiotic resistance of pathogenic species is by using new compounds that are not based on 
existing synthetic antimicrobial agents (Bessong et al., 2005; Rojas et al., 2006). Traditional 
practitioners also claim that some medicinal plants such as Lippia spp are more efficient to 
treat infectious diseases than synthetic antibiotics. It is necessary to evaluate, in a scientific 
base, the potential use of folk medicine for the treatment of infectious diseases produced by 
common pathogens. Reports have documented the existence of many plants in Africa used by 
traditional medical practitioners which they claim are efficient in the management of 
complaints symptomatic of peptic ulcer diseases; a major outcome of H. pylori infection. 
However, the claims are not substantiated with scientific facts, though continuous usage of 
these plants in the management of infections indicates that the plants may contain 
constituents, which have antibacterial activities.  
Medicinal plants represent a rich source form which antimicrobial agents may be obtained. 
Plant extracts have a positive impact on the treatment of gastroenteritis and other infectious 
diseases caused by bacteria. Exploration of newer antimicrobials in plants brings about a 
different approach in minimizing antibiotic resistance (Huang et al., 2004; Umeh et al., 
2005). Hence, a more detailed search for new antimicrobial drugs is needed.  
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As antimicrobial resistance to antibiotics increases globally, development of novel drugs is 
imperative and there has been an improved interest in ethnopharmacological research 
globally. According to studies in the literature, there is evidence that natural antimicrobials 
can act as resistant microbial inhibitors (Sofowera et al.,  1993;  Adebolu, 2005). Studies are 
generally of a screening nature, and investigate biological activities such as antioxidant, 
antibacterial, anti-inflammatory and antifungal properties of extracts from medicinal plants 
usually based on ethnobotanical leads.  
Plants have been documented to have compounds that contribute to their antimicrobial 
activity including phytochemals such as flavanoids, phenolics, and propolis (Harbourne, 
1983; Cushnie and Lamb, 2005; Xuan et al., 2005) which are not fully characterized but 
possess antimicrobial activity against bacterial pathogens. Phytochemicals are substances that 
are produced naturally by plants. They contribute to the plant self-defence mechanisms by 
protecting the plant against bacteria, fungi and viruses. They have been described as non-
peroxide antimicrobial factors. It is believed that these pytochemical factors are composed of 
many complex phenols and organic acids.  
Some of these compounds like polyphenols have been shown to exert their antibacterial 
action through membrane perturbations. This perturbation of the cell membrane coupled with 
the action of β-lactams on the transpeptidation of the cell membrane could lead to an 
enhanced antimicrobial effect of the combination (Esimone et al., 2006). It has also been 
shown that some plant derived compounds can improve the in vitro activity of some 
peptidoglycan inhibiting antibiotics by directly attacking the same site (that is, peptidoglycan) 
in the cell wall (Aiyegoro et al., 2009).  
The use of plant as an antimicrobial may inhibit bacteria by a mechanism different from an 
antibiotic, thus may contribute to the treatment of resistant microbial pathogens. As a result 
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of this, a number of investigations have been reported by authors on the screening of plants as  
natural antimicrobials (Adebiy et al., 2004; Adebolu, 2005; Viljoen et al.,2005; Ndip et al., 
2008). Medicinal plants have had a great positive impact on the treatment of gastroenteritis 
and other infectious diseases caused by bacteria. Exploration of newer antimicrobials in 
plants brings about a different approach in minimizing antibiotic resistance, and thus offers 
potential benefits. 
 
2.8.1 Lippia javanica 
The genus Lippia (Houst.), a member of the Verbenaceae family is represented by 
approximately 200 herbs, shrubs and small trees which are often of an aromatic nature 
(Terblanche and Kornelius, 1996). The species are widely distributed in tropical and Southern  
Africa as well as  throughout South and Central America with the exception of the Western 
Cape (Velasco-Negeureula et al., 1993; VanWyk et al., 1997). Lippia javanica (Burm. f.) 
Spreng is one of the four indigenous Lippia species in South Africa where it occurs as an 
erect woody shrub approximately 2m in height. The stems have a square appearance when 
looked at in cross-section. The leaves are hairy with noticeable veins and when crushed gives 
off a strong lemon-like smell.  The small cream flowers can be found on the shrub from 
summer to autumn in some areas and in others are produced all year. These flowers are 
arranged in dense, rounded flower heads. The fruit are rather inconspicuous, small and dry.  
The plant is used extensively in traditional medicine by both lay people and traditional 
healers to treat minor ailments (Pascual et al., 2001). Many of its uses relate to microbial 
infections, e.g. coughs or colds and also for skin infections or wounds. The leaves and stems 
are often used and in some cases the roots as well (Van Wyk et al., 1997). Strong leaf 
infusions are made which are commonly used as inhalants. The leaf infusions are also used 
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topically for scabies and lice (Gelfand et al., 1985;VanWyk et al., 1997). An infusion of the 
leaves is commonly used as a decongestant for colds and coughs as well as diarrhoea (Viljoen 
et al., 2005). Its use has excelled in the treatment of respiratory aliments traditionally, which 
may either be fungal or bacterial and also in the treatment of Gram-negative and yeast borne 
respiratory aliments (Viljoen et al., 2005). More commonly, leaf and stem infusions are used 
as a tea, and this is taken to treat coughs, colds, fever and bronchitis (Hutchings, 1996).  
The plant has also been used for bronchial ailments and influenza (Hutchings, 1996). The 
Vhavenda people use leaf infusions as anthelmintics, for respiratory and febrile ailments and 
as prophylactic against dysentery and malaria (Mabogo, 1990). Roots are used as antidotes 
for suspected food poisoning and for bronchitis and sore eyes (Hutchings, 1996). L. javanica 
has also been used as a mosquito repellent by the population in Southern Africa for a long 
time and previous studies in Zimbabwe have shown that essential oils from L. javanica have 
very strong and lasting repellent activity against starved female Anopheles arabiensis (Omolo 
et al., 2005). However, other studies in Durban and Venda showed that the extracts of L. 
javanica were not active against E. coli and other bacteria (McGaw et al., 2000; Samie et al., 
2005).  
The acetone and methanol extracts of L. javanica were found to be active against most 
bacteria including B. subtilis, P. mirabilis and S. marcescens and S. aureus. (Same et al., 
2005). The antimicrobial activities of this plant are said to be due to some chemotypes, 
including limonene, germacrene-D, camphon, linalool, β-caryophyllene, myrcene and 
genanial (Velasco-Negeureula et al., 1993; Terblanche and Kornelius, 1996). L. javanica is 
administered in the form of thin leaves and teas, it is most probable that the non-volatile 
compounds could be acting in a synergistic/ additive manner to produce enhanced chemical 
properties (Viljoen et al., 2005).  
41 
 
Neidlein and Staehle (1974) reported the presence caryophyllene, linalool and p-cymene 
while Chagonda et al. (2000) documented variations in major essential compounds in the 
plant in samples taken from the same location in Zimbabwe e.g. linalool, which had a range 
between 1.7 and 27%. Also, Ngassapa et al. (2003) reported a geranial and neral chemotype 
from Tanzania. Essential oils are known for their antimicrobial properties.  
The use of synthesized compounds in the treatment of chronic diseases is rendered ineffective 
due to the alarming resistance of microorganisms to antibiotics, however, the potential use of 
plant based medicine is more effective and a cheaper alternative, which is probably 
responsible for the fast growing industry of herbal medicine (Ghaemi et al., 2007; Hassan et 
al., 2007). Plants are used medicinally in different countries and are a source of many potent 
and powerful drugs (Kubmarawa et al., 2007). Many natural occurring compounds found in 
medicinal plant extracts have also been shown to posses antimicrobial activities that inhibit 
the growth of microorganisms (Katsvana and Chigwaza, 2004; Ndip et al., 2008). The active 
principles of many drugs found in plants are secondary metabolites (Kubmarawa et al., 
2007). Therefore, basic phytochemical investigation of these extracts for their major 
phytoconstituents is also vital. However, different solvent extracts of plants have different 
phytochemical properties (Hassan et al., 2007). 
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CHAPTER THREE 
 MATERIALS AND METHODS  
3.1 Bacterial strains 
A total of 31 H. pylori strains isolated and characterized based on our previously reported 
schemes (Ndip et al., 2008; Tanih et al., 2010) from patients presenting with upper 
gastrointestinal complaints at the Livingstone hospital in Port Elizabeth were used after 
informed consent and ethical clearance from the Department of Health, Eastern Cape 
(Protocol number EcDoH-Res 0002) and institutional review board of the University of Fort 
Hare. A reference strain of H. pylori (NCTC 11638) was included as a control. 
 
 3.2 Preparation of plant extracts 
The plant was selected based on ethnobotanical information and identified   in collaboration 
with botanists of the University of Venda, Limpopo Province, where voucher specimens have 
been deposited (number AS 19).  Lippia javanica leaves were harvested, air dried for 2 weeks 
and ground to fine powder. Dried plant material, 2.5 - 2.8 kg, was macerated in five fold 
excess of solvent (ethanol, ethylacetate, methanol, chloroform or water) in extraction pots 
such that the level of the solvent was above that of the plant material. The slurry was allowed 
to stand at room temperature (RT) for 48h and filtered using filter paper of pore size 60Å. 
The process was done 3 times. The combined extracts were concentrated in a rotavapor 
(BUCHI R461, Switzerland) and transferred to appropriately labelled vials and allowed to 
stand at RT to permit evaporation of residual solvents. A stock solution was prepared by 
dissolving the extracts in 10% Dimethyl Sulphoxide (DMSO) (Okeleye et al., 2010). 
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3.3 Antimicrobial susceptibility testing 
The agar well diffusion method, which conforms to the recommended standards of the 
Clinical and Laboratory Standards Institute (CLSI), was used as previously described (Ndip 
et al., 2007). Brain heart infusion (BHI) agar (Oxoid,UK) was used. Wells were made in each 
plate using a sterile cork borer. The bacterial inoculum was prepared from subcultures of 
bacteria as follows: four to five colonies of the isolates were emulsified in sterile normal 
saline and the turbidity adjusted to 1.5 × 10
8
 CFU/mL (corresponding to 0.5 McFarland 
standards). A sterile cotton swab was dipped into the standardized bacterial suspension and 
used to evenly inoculate the BHI agar plates. Plates were allowed to dry for 3 to 5 minutes. 
Thereafter, 0.1 mL of the plant extracts (10-20 mg/mL) were filled into each well separately. 
Clarithromycin (0.05 μg/mL) was used as the positive control. DMSO was used as negative 
control. The plates were incubated at 37 °C for 2–5 days. They were then examined and the 
diameter of the zone of inhibition measured in millilitres. H. pylori control strain NCTC 
11638 was included in all the experiments. Each experiment was replicated three times. 
 
3.4 Determination of minimum inhibitory concentrations (MIC) 
Extracts that gave a zone of inhibition ≥ 15mm were chosen for MIC determination.  The 
MIC was determined using a microdilution test (Banfi et al., 2003; Samie et al., 2005) with 
modifications. Two-fold dilutions of each extract was prepared in the test wells in complete 
BHI supplemented with 5% horse serum (Oxoid, England) and Skirrow‘s supplement (Oxoid, 
England). The final extract concentrations ranged from 0.0048 –10 mg/mL. Each strain was 
sub-cultured in 2 mL of BHI broth for 2 days and the turbidity adjusted by adding 0.5mL to 
4.5mL of normal saline and then serially diluted to correspond to 0.5 McFarland standards. 
Twenty five microlitres of each bacterial suspension was added to 175 μL of extract-
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containing culture medium. Control wells were prepared with culture medium and bacterial 
suspension only. Control antibiotics included amoxicillin and metronidazole. The plates were 
sealed and incubated under microaerophilic condition for 3 – 5 days at 37°C, after which 32 
μL of resazurin solution was added per well, colouring them blue. Plates were incubated at 
37°C for an additional 1hour. Plates were observed for colour change from blue to pink in 
live H. pylori -containing wells and then read with a microtiter plate reader adjusted to 
620nm (Model 680 Bio-Rad, Japan). MIC was defined as the lowest concentration of extract 
that prevented resazurin solution colour change from blue to pink resulting in inhibition of 
90% & 50% of bacterial growth (MIC90 & MIC50 respectively). Each MIC was determined 
three times. 
 
3.5 Determination of rate of kill 
The method described by Akinpelu et al. (2009) was used to determine the rate of kill with 
modifications.  Turbidity of an 18 h old test organism was first standardized to 10
8
cfu/mL. A 
0.5 mL volume of known cell density from each strain suspension was added to 4.5 mL of 
BHI broth supplemented with 5% horse serum and Skirrow‘s supplement (Oxoid, England) 
this was then incorporated with the extract at ½× MIC, MIC, 2× MIC and 4× MIC and 
incubated at 37
o
C on an orbital shaker at 120 rpm. The rate of kill was determined over a 
period of 72 h at 6 h interval. A volume of 0.5 mL of each suspension was removed from 
cultures at time intervals and transferred to 4.5 mL of BHI broth and recovery medium 
containing 3% Tween-80 to neutralize the effects of the crude extracts carryovers from the 
test suspensions. The suspension was then serially diluted and plated out for viable counting. 
The plates were later incubated microaerophilically at 37
o
C for 72 h. The control plates 
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included extract free BHI broth seeded with the test inoculum. Visible bacterial colonies were 
counted and compared with the counts of the culture control. 
 
3.6. Phytochemical Analysis 
A small portion of the dry extract was subjected to phytochemical test using the method of 
Adegboye et al. (2008) to test for alkaloids, tannins, flavonoids, steroids, saponins. 
3.6.1 Test for alkaloids 
Approximately 0.5g of the plant extract was dissolved in 5 mL of 1% HCl on steam bath. A 
millilitre of the filtrate was treated with drops of Dragendorff‘s reagent. Turbidity or 
precipitation was taken as indicative of the presence of alkaloids. 
3.6.2 Test for tannins 
One gram of the extract was dissolved in 20 mL of distilled water and filtered. Two to three 
drops of 10% FeCl3 was added to 2 mL of the filtrate. The production of a blackish-blue or 
blackish-green colouration indicated the presence of tannins. To another 2 ml of the filtrate 
was added 1 ml of bromine water. A precipitate was taken as positive for tannins. 
3.6.3 Test for flavonoids  
Approximately 0.2g of the extract was dissolved in 2 mL of methanol and heated. A chip of 
magnesium metal was added to the mixture followed by the addition of a few drops of 
concentrated HCl. The occurrence of a red or orange colouration indicated the presence of 
flavonoids. 
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3.6.4 Test for saponins 
Agar well diffusion was used to test for saponins. A freshly prepared 7% blood agar medium 
was used. The extract in methanol was added to distilled water; methanol was used as a 
negative control while commercial saponin (BDH) solution served as a positive control. The 
plates were incubated at 35
0 
C for 6h. Complete haemolysis of the blood around the extract 
was an indicative of saponins. 
3.6.5 Test for steroids 
About 0.5 g of the extract was dissolved in 3 mL of CHCl3 and filtered. Concentrated 
Sulphuric acid was added to the filtrate to form a lower layer. A reddish brown colour was 
taken as a positive for steroids. 
 
3.7 Statistical analysis 
Analysis of data was performed using SPSS Version 17.0 (Illinois USA, 2009). The ANOVA 
test was used to determine if there was any statistically significant between plant extracts and 
antibiotics; the MIC of the most active extract and the control antibiotics. P-values <0.05 
were considered significant. 
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CHAPTER FOUR  
     RESULTS  
4.1 Antimicrobial susceptibility testing 
A total of 31 strains were screened for susceptibility to the crude extracts of L. javanica 
(Table 1). A zone of inhibition of ≥15mm of the crude extract was chosen as representative of 
susceptibility to the tested strains. All the extracts demonstrated antimicrobial activity with 
zone diameter ranging from 0 - 36mm. The acetone extract exhibited the best activity with a 
zone diameter of 15 - 36mm. All the test strains were susceptible to the acetone extract 
(100%), whilst the least activity (16%) was observed for water extract at 10 - 20 mg/mL 
(Table 1). The concentration of 10% DMSO had no effect on the bacterial growth. The mean 
zone diameter of inhibition the acetone extract was statistically significant (P<0.05) 
compared with the other extracts and the control antibiotic, clarithromycin (Table 2).  
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Table 1 Zone inhibition diameter (mm) of the crude extracts of L. javanica and antibiotic. 
       
                                         mg/ml     
Bacterial strains Acetone Ethanol Methanol Chloroform Water 
 
Claritromycin 
       
PE2A 25 16 12 24 9 14 
PE5A 26 16 12 13 10 19 
PE9C 23 15 12 0 8 32 
PE11A 20 13 11 15 0 23 
PE11C 21 15 12 12 0 11 
PE14C 24 13 12 10 0 8 
PE252C 23 15 13 13 8 29 
PE369A 23 20 15 18 0 20 
PE 369C 18 12 15 7 12 18 
PE397C 34 27 19 20 9 0 
PE402A 15 8 8 7 8 12 
PE406C 22 13 24 10 18 12 
PE407C 19 12 15 10 0 22 
PE411A 22 15 15 15 10 14 
PE411C 21 12 15 13 10 16 
PE430A 24 16 15 10 30 23 
PE430C 15 15 15 7 12 35 
PE435A 22 15 10 15 10 20 
PE435C 24 13 11 8 11 8 
PE436A 20 15 19 18 13 13 
PE436C 24 12 15 13 10 12 
PE462A 19 10 8 7 11 18 
PE462C 19 13 15 7 8 17 
PE466A 36 15 15 16 20 15 
PE466C 26 25 24 15 15 19 
PE 467A 25 19 24 18 8 0 
PE467C 26 20 24 7 19 0 
PE469A 18 15 15 16 12 12 
PE469C 20 15 13 18 13 8 
PE 471A 23 12 17 12 11 0 
PE471C 24 12 13 11 12 0 
       
Average 100% 58.00% 60.00% 39% 16% 55% 
 
Average was calculated as number of strains that gave the zone diameter of inhibition ≥15 
mm divided by the total number of strains.  This then showed the number of strains that were 
inhibited by extracts and the control antibiotic. 
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Table 2 Mean zone diameter of inhibition of the crude extracts (L. javanica) and antibiotics.  
 
Extract / control antibiotic 
 
Mean zone of  diameter of 
inhibition (mm) 
 
Inhibition diameter range 
 
P-value  
 
L.jav. (A) 
 
22.61±4.432 
 
15 – 36 mm 
 
0.041 
L.jav. (E) 14.97±3.920 8 – 27 mm 0.062 
L.java. (M) 14.94±4.36 8 – 24 mm 0.061 
L.jav. (Chl) 12.92±4.985 0 – 24 mm 0.082 
L.jav. (W) 10.23±6.39 0 – 30 mm 0.091 
Control antibiotic (Clr) 15.42±8.732 0 – 35 mm 0.060 
    
L.jav= Lippia javanica; A=Acetone, E=Ethanol, M=Methanol, Chl=Chloroform, W=Water, 
Clr=Clarithromycin 
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4.2 Minimum Inhibitory Concentration (MIC) determination 
The MIC of the extracts ranged from 0.00195 - 0.625 mg/mL for acetone at MIC50 and 
0.0048 - 0.625 mg/mL (MIC50) for metronidazole and amoxicillin respectively. On the other 
hand MIC90 ranged from 0.039 - 0.625 mg/mL for acetone, 0.0097 - 5 mg/mL for 
metronidazole and 0.039 -> 2.5 mg/mL for amoxicillin. The activity of the acetone extract 
was statistically insignificant (P > 0.05) compared to the other crude extracts and antibiotics.  
 
Table 3 In-vitro anti-H. pylori activity of L. javanica  extracts and antibiotics at MIC50 and 
MIC90 in mg/mL. 
 
Bacterial 
strains Acetone  Methanol Ethanol  Metronidazole Amoxicillin   
 MIC50 MIC90 MIC50 MIC90 MIC50 MIC90 MIC50 MIC90 MIC50 MIC90   
PE2A 0.078 0.156 0.078 0.156 >0.039 0.313 0.039 ND 0.078 0.313   
PE5A 0.25 ND 0.039 0.625 0.039 >0.313 0.0048 >2.5 0.0048 0.625   
PE9C 0.078 0.625 ND 0.156 0.039 0.156 0.125 0.625 0.156 ND   
PE11A 0.078 0.313 0.078 0.156 0.039 0.625 0.125 0.625 0.078 0.25   
PE11C 1.25 0.313 1.25 1.25 1.25 0.0078 0.039 0.156 0.039 0.313   
PE14C 0.039 ND 0.078   ND 0.039 0.313 ND 2.5 0.625 0.078   
PE252C 0.078 0.156 0.078 0.156 0.039 0.313 0.00975 ND 0.00975 ND   
PE369A ND 0.313 0.625 1.25 ND 0.313 ND ND 1.25 >0.125   
PE 369C 0.039 0.156 0.039 0.156 0.00195 0.156 0.00975 >5 0.078 >2.5   
PE397C 0.039 0.156 0.078 0.156 0.0095 0.313 ND ND 0.078 0.039   
 
51 
 
PE402A 0.039 0.156 0.039 0.156 0.039 0.078 0.313 0.625 0.039 0.078   
PE406C 0.039 1.25 0.039 0.625 0.00195 0.313 0.00975 >2.5 0.00975 ND   
PE407C 1.25 0.625 1.25 0.625 0.625 0.0078 0.078 >0.156 0.039 0.625   
PE411A 0.078 0.156 0.039 0.078 ND ND ND ND 0.0048 0.313   
PE411C 0.625 1.25 0.313 1.25 2.5 0.313 0.00975 ND 0.0048 0.156   
PE430A 0.0048 0.039 1.25 0.625 ND 0.039 0.00975 ND 0.039 0.156   
PE430C 0.039 0.625 0.039 0.625 ND 0.039 0.078 >2.5 0.078 >0.313   
PE435A 0.156 ND 0.039 0.156 0.156 ND ND ND 0.0048 1.25   
PE436A 0.00195 ND 0.078 0.625 0.00195 0.078 0.0048 ND 0.0048 ND   
PE436C 0.0095 0.156 0.625 0.313 0.00195 0.078 0.0048 0.00975 0.0048 0.625   
PE462A 0.039 2.5 0.039 0.156 0.00195 0.313 0.00975 ND 0.00975 ND   
PE462C 0.039 0.625 0.039 0.156 0.00195 0.156 0.00975 ND 0.00975 ND   
PE466A 0.156 ND 0.078 0.156 0.156 ND 1.25 2.5 0.078 0.039   
PE466C 0.00195 0.625 0.039 0.156 0.00195 0.078 0.00195 ND 0.00195 ND   
PE467A 0.00195 0.156 0.039 0.313 0.0095 0.078 0.0048 ND 0.0048 0.625   
PE467C 0.039 0.156 0.00195 0.078 0.078 0.00975 0.0048 ND 0.078 0.313   
PE469A 0.039 0.078 0.039 0.156 0.00195 0.039 0.625 ND 0.078 0.039   
PE469C 0.039 0.313 0.156 0.039 0.078 0.00195 0.0048 1.25 0.0048 0.125   
PE471A 0.078 0.156 0.039 0.156 0.039 0.078 0.0048 ND 0.0048 0.313   
PE471C 0.039 0.078 0.0048 0.156 0.0048 0.156 0.0048 1.25 0.0048 0.313   
Average 0.173 0.45 0.225 0.29 0.21 0.152  0.126  1.06 0.12   0.26   
 
*ND- Not determined  
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4.3 Determination of rate of kill 
The bactericidal activity of extracts against the H. pylori strains was determined using time-
kill essay. A significant decrease in mean viable count of isolates at each time interval was 
observed. 
The acetone extract was bactericidal against PE369C at MIC and 2× MIC after an 18h 
interaction period. At 4× MIC, the extract was bactericidal to PE466C at 0h-72h interaction 
(Figure 1a and 1b) period; an increase in colony count was observed at the 54h interval, and 
then a sudden decrease was observed at 60h-72h interaction period. At ½× MIC, a 
remarkable decrease in colony count was observed after a 24h interaction period; and an 
increase was then observed after the 36h. On the other hand, the ethanol extract exhibited 
bactericidal effect against PE369C and PE466C at 2× MIC and 4× MIC during the 6h-72h 
interaction period with complete inhibition of the bacterial strains (Figure 2a and 2b). 
Complete inhibition was also observed for PE369C at ½× MIC and MIC at 6h-36h 
interaction period. The ethanol extract also showed remarkable results by further inhibiting 
the growth of PE252C at 2× MIC and MIC at 0hr-72hr interaction period, whilst at ½× MIC 
and MIC, the bactericidal effect was observed after the 12h and 36h interaction periods 
respectively. 
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(a) 
 
(b) 
 
Figure 1: Profile of rate of kill of H. pylori strain (a) PE 466C and (b) PE 369C by acetone extract of 
L. javanica as compared to negative control (H. pylori strain). The concentration of the extracts used 
in these experiments  were  4× MIC (0.4 mg/ml), 2× MIC (0.2 mg/ml), 1×MIC (0.1 mg/ml) and ½× 
MIC (0.05 mg/ml). 
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( c) 
 
(d) 
 
Figure 2: Profile of rate of kill of H. pylori strain (c) PE 369C and (d) PE 252C by ethanol extract of 
L. javanica as compared to negative control (H. pylori strain). The concentration of the extracts used 
in these experiments  were 4× MIC (0.4 mg/ml), 2× MIC (0.2 mg/ml), 1×MIC (0.1 mg/ml) and ½× 
MIC (0.05 mg/ml).  
55 
 
4.4 Phyto-chemical analysis 
Phytochemical analysis of the acetone and ethanol leaf extract of L. javanica revealed the 
presence of the following secondary metabolites: flavanoids, saponins, tannins, steroids and 
alkaloids (Table 4). The presence of precipitate or turbidity was an indicative for the presence 
of alkaloids, tannins. 
 
 
Table 4 Phytochemical screening of the acetone and ethanol extract of L. javanica. 
 
Components  
 
Reaction 
Acetone 
 Reactivity 
Ethanol 
Alkaloids 
Flavanoids 
Turbid/Precipitate 
Red/Orange color 
+++ 
+++ 
+++ 
+++ 
Tannins Blackish-green/Precipitate ++ ++ 
Steroids Reddish Brown Color +++ +++ 
Saponins Complete Haemolysis +++ +++ 
    
Key: +++; Strongly present; ++; Moderately present; +; weakly present 
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CHAPTER FIVE  
 
5.1 DISCUSSION AND CONCLUSION 
 
Antibiotic resistance is a worldwide phenomenon. Currently, antibiotic resistance by bacteria 
has become a worrisome phenomenon in developing countries, especially in sub-Saharan 
Africa. This situation is more likely related to the recurrent use or misuse of drugs (Mulu et 
al., 2004). The antimicrobial effects of various plants have been well documented for 
centuries, especially in traditional medicine (Nostro et al., 2000; Gislene et al., 2000; Nostro 
et al., 2005). Findings from previous studies have documented plant based substances known 
to exhibit a very good inhibitory effect. This has led to a search for antimicrobials that could 
inhibit various drug-resistant microorganisms (Li et al., 2005; Steenkamp et al., 2007). This 
study investigated the anti-H. pylori activity of Lippia javanica, a South African medicinal  
plant, in a bid to find potential source of active anti-H. pylori agents that could be cheap, 
readily available. 
The plant was investigated for anti-H. pylori properties. Most of the extracts exhibited 
antimicrobial activity with an inhibition zone diameter of ≥15 mm by agar well diffusion 
assay. Precisely the zones ranged from 0 – 36 mm (Table 1). Our result corresponds with the 
findings of Atapour et al. (2009), who also reported an inhibition zone diameter of ≥15 mm 
of their medicinal plant extracts of Bunium persium, Heracleum persium, myrtus communis, 
Nigella sativa,  Pimpella anisum, Salvia mirzayanii, Teucrium polium, Zataria multifllora 
against clinical isolates of H. pylori. Among the plants tested, Salvia mirzayanii, Heracleum 
persicum, Zataria multiflora, and Teucrium polium exhibited the strongest anti-H. pylori 
activities with a diameter range of 20 – 30 mm. This is also in line with a study conducted by 
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Ndip et al. (2007), that revealed the antimicrobial activity of plant extracts of Ageratum 
conyzoides; Scleria striatinux; Lycopodium cernua; Emilia coccinea; Eryngium foetidium; 
Euphorbia hirta, Tapienachilus ananassae; Aulatandria kamerunensis; Acanthus montanus 
and Scleria verucossa  against the tested isolates with the zone of inhibition ranging from 0-
30 mm. Samie et al. (2009) screened 16 South African medicinal plants including L. javanica 
against Campylobacter isolates; and reported an MIC ranging from 1.25 - 10 mg/mL. 
According to their findings, L. javanica and Ptenocarpus angolensis extract exhibited the 
strongest inhibitory activity compared to other plant extracts tested. To achieve effective 
treatment, antimicrobials that can penetrate a cell at high concentrations should be chosen and 
the duration of the therapy should be set properly (Huang et al., 2004). The results revealed 
that L. javanica extracts were able to inhibit the growth of H. pylori at concentrations ranging 
from 10 - 20 mg/mL. 
Acetone and methanol extracts of several plants show promise as templates for the design of 
new anti-H. pylori therapies.  In this study, the acetone crude extract was observed to be the 
most active against all the tested strains of H. pylori. The crude extract exhibited a 100% 
inhibition, followed by ethanol extract (60%) and methanol (58%). The least activity was 
observed for the aqueous extract (16%). This is in line with previous studies, which also 
documented the inhibitory effects of methanolic extracts of medicinal plants (Ndip et al., 
2008).  
Also, the acetone and methanol extracts of L. javanica were found to be active against most 
bacteria responsible for respiratory aliments (Samie et al., 2005), which is in line with our 
results. The results of this study revealed that water extract exhibited poor antimicrobial 
activity as compared to other extracts at 10 - 20 mg/mL where only 16% of the strains were 
inhibited with a zone of inhibition ranging from 0 - 30 mm. However, Steenkamp et al. 
(2007) reported that aqueous extracts of 16 plant species including Afzelia quanzensis, 
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Asparagus falcalus Thumb, Bruckenridgea zanguebarica, Bridelia macarantha, Burkea 
Africana, Combretum molle,  Ficus sycomorus L, and Peptoforum africanum sond inhibited 
Candidiasis growth.  
Organic solvents are better for more consistent extraction of antimicrobial substances from 
medicinal plants compared to other solvents (Kubmarawa et al., 2007; Arif et al., 2009). 
Literature documents that Ficus sycomorus organic stem extracts exhibited higher antifungal 
activity than the aqueous extracts (Kubmarawa et al., 2007; Hassan et al., 2007; Meda et al., 
2008). However, Arif et al. (2009) documented that chloroform extract of Caesalpinia 
bonduc seed exhibited antimicrobial activity against all tested bacterial strains except 
Staphyloccocus aureus and Pseudomonus  aeruginosa. According to our results, although 
chloroform extracts showed an inhibitory effect against H. pylori strains with a zone diameter 
of inhibition ranging from 0 - 18 mm, compared to other extracts, the tested isolates were 
39% susceptible to chloroform extract. This plant has been used in folk medicine as a 
mosquito repellent in various parts of South Africa for centuries as well as in Zimbabwe 
where a significant activity of the essential oils have been shown with a lasting repellent 
activity against starved Anopheles arabienis (Katsvanga and Chigwaza, 2004; Samie et al., 
2005). Bergonzelli et al. (2003) reported the antimicrobial effects of essential oils of C. carvi 
which however remained weakly active against H. pylori. 
The differences in the observed activities of the various extracts may be due to varying 
degrees of solubility of the active constituents in the five solvents used. It has been 
documented that different solvents have diverse solubility capacities for different phyto-
constituents. However, previous studies have shown that the solvents used in extraction affect 
the antimicrobial activities of plants. It is known that different solvents extract different 
compounds, implying that some bioactive components can only be extracted by polar 
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solvents while others by less polar and yet some by non-polar solvents (Ogundare et al., 
2006; Ndip et al., 2007; Njume et al., 2009).  
Compared with clarithromycin, the extracts showed inhibitory effects on the growth of H. 
pylori at higher concentrations; however, the results suggest that the extracts have a 
considerable antibacterial activity against H. pylori. The results revealed that the tested 
strains were 55% susceptible to clarithromycin. Tanih et al. (2010) recently documented that, 
H. pylori strains were 80% susceptible to clarithromycin. However, microorganisms have 
been reported to be resistant to clarithromycin by other investigators (Franzin et al., 2000; 
Wang et al 2000; Pace et al., 2007). Although clarithromycin is an expensive macrolide, 
cross-resistance linked with the use of other less expensive macrolides may be responsible for 
this resistance, since it is not used frequently by patients. However, clarithromycin-
susceptible and resistant strains have been identified from patients with no history of 
exposure to macrolides, which may suggest that administration of clarithromycin may select 
for the resistant strains and therefore must be guided by empirical treatment (Tanih et al., 
2010). The difference in the antimicrobial activities of plants and antibiotics can be a result of 
difference in quality and variety of compounds found in a plant. As well as for antimicrobials 
to be effective, they must attain a sufficient high concentration at target site in order to exert 
their antibacterial action (Adeleke et al., 2004).   
In the current study, it was revealed that amongst the extracts evaluated for MIC; acetone, 
methanol and ethanol extracts exhibited the strongest antimicrobial activity; the least was 
observed for chloroform and water extracts (Table 3). It was observed that the MIC ranged 
from 0.00195 - 0.25 mg/mL for acetone extracts (MIC50), while the methanol extract ranged 
from 0.00195 - 0.625 mg/mL.  Ndip et al. (2007) reported a similar finding with an MIC 
range of 0.1698 - 0.2336 mg/mL for the methanol extracts of some plants tested against H. 
pylori strains. Atapour et al. (2009) also documented strongest antimicrobial activity of S. 
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mirzayanii plant extract against clinical isolates of H. pylori with an MIC ranging from 32 – 
64 μg/mL. In another study, the methanol extract of the seeds of C. carvi had a MIC value of 
100 μg/mL(Mahady et al., 2005; Atapour et al., 2009). The results also correspond with the 
investigation conducted by Same et al. (2009) on Campylobacter isolates; acetone and 
methanol extracts of the plant were active at a MIC range of 0.09-6 mg/mL. Aiyegoro et al. 
(2009) also reported activity for acetone and methanol crude extract of Helichrysum 
longifolium with a MIC range of 0.5 - 5 mg/mL on two isolates of Pseudomonas aeruginosa 
ATCC 19582 at a concentration of 0.1 mg/mL. 
The MIC values of the extracts and antibiotics were statistically compared to determine any 
variation in their efficacy against the isolates. No statistically significant difference (P > 0.05) 
was observed between the MIC and antibiotic values of the five extracts. Ndip et al. (2007) 
compared MIC and MBC values of three plant extracts which revealed no statistically 
significant difference (P > 0.05) against H.pylori isolates. Li et al. (2005) recorded anti- H. 
pylori actions with MIC range of 60μg/mL on ethanol extracts of Hippophae rhamnoides, 
Fritillaria thunbergii, Magnolia officinalis and Schisandra chinensis, Corydalis yanhusuo, 
Citrus reticulata, Bupleurum chinense and Ligusticum chuanxiong. The results recorded 
MIC50 of ethanol extract ranging from 0.00195 - 2.5 mg/mL. On the other hand, MIC90 of 
ethanol extract ranged from 0.00975 - 0.313 mg/mL. High MIC values however, is an 
indication of lack of efficacy of the plant extracts against the test bacteria and/or the 
possibility that the bacteria may possess the capacity to develop resistance against the plant 
extracts. Thus, variable consequent activity of a plant and its components have been 
identified according to geographical strata of the plant at a time, as plant material may be 
collected at different times as well as different regions that might have contributed to 
different activities of the plant on the tested bacteria (Samie at al., 2005; Viljoen et al., 2005; 
Atapour et al., 2009; Oliver et al., 2009). 
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The varied activities reported in the different studies may be attributed to the type of bacterial 
species studied, the extracts, and the potential difference in plant chemistry of different 
samples as well as the season in which the plants were collected. Climate changes are 
amongst other factors that have been reported to affect antimicrobial activity of plants (WHO, 
1992). Also, the antimicrobial effects of L. javanica might be due to some phytochemicals 
present in the plant including; linalool, β-carophyllene, and myrcene. It has been documented 
that essential oils of this plant are active against most bacterial species tested (Samie et al., 
2005; Viljoen et al., 2005). The antimicrobial activity of the plant may be directly related to 
the specific composition of the oil, therefore, activity of the plant may also fluctuate (Viljoen 
et al., 2005). It has also been reported that three compounds from L. javanica are able to 
inhibit the HIV-1 transcriptase enzyme (Fritz et al., 2006; Oliver et al., 2009). 
The time-kill assay was performed to investigate the bactericidal activity of L. javanica on 
selected H. pylori strains. L. javanica was tested on the basis of MIC‘s obtained in the study. 
Comparison of the time kill plots of the ethanol and acetone extracts studied showed that the 
killing rate was greater for ethanol extract and very little reduction of microbial population 
was observed for the acetone extracts.  Akinpelu et al. (2009) reported the bactericidal 
activities of the fractions of G. kola using viability studies. As the concentration of the 
fractions increased, the microbial population decreased. However, in the results obtained the 
efficacy of acetone and ethanol crude extract showed a killing rate within 0 - 12 h at all 
concentrations being tested. A greater effect of inhibition was shown with ethanol crude 
extract having the ability to inhibit the growth of H. pylori at 4× MIC as well as 2× MIC for a 
period of 72 h. To a lesser extent, the growth of H. pylori decreased at concentrations of ½× 
MIC, MIC, and 2× MIC within a period of 18h and a sudden increase in colony count was 
observed at 36h. This might be due to the fact that H. pylori is a slow grower. A reduction in 
colony count was then observed at ½× MIC and MIC after the 36h. 
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These results are interesting and justifies the use of L. javanica in the treatment of aliments‘ 
that are due to bacterial infections. The bactericidal activities of the crude extracts on the 
clinical isolates used in this study are worth noting, because these strains were isolated from 
gastric presenting patients. The inhibitory levels of the crude extracts of the plant was 
bacteriostatic or bactericidal. Also, the rate of kill of the extract appeared to be both 
concentration and time dependent which corresponds with other studies (Same et al., 2005; 
Ali et al., 2005; Akinpelu et al., 2009). 
 
The phytochemical analysis of the extract of L. javanica revealed the presence of flavonoids, 
tannins, steroids, saponins and alkaloids. The presence of alkaloids which turned out to be 
strongly active, is a manifestation that this plant species (Lippia javanica) can be a very good 
source of medicine. Since some of the 30 known alkaloids are used in medicine today, we 
think that, it is important for the specific type of alkaloid present in the leaves of the L. 
javanica plant be isolated in the near future. Further, flavonoids present in the leaves are an 
indication of the plant‘s antiviral, antifungal, anti-inflammatory and cytotoxic activities 
(Ezeifeka et al., 2004).  These phytochemical compounds are known to play important roles 
in bioactivity of medicinal plants and as such, produce definite physiological actions on the 
human body (Kamboj et al., 2008; Kamboj et al., 2009). Several reports on flavonoids, 
triterpenoids and steroids, which are part of the phytochemical constituents of L. javanica, 
showed that these molecules exhibit a wide range of biological activities, one of which is 
their ability to scavenge for hydroxyl radicals (free readicals), and superoxide anion radicals, 
and thus health promoting in action (Ferguson, 2001; Tasleem, 2009). 
Literature has also documented the antimicrobial and resistance modulating potentials of 
naturally occurring flavonoids and polyphenolic compounds (Just et al., 1998; Mansouri et 
al., 2001; Hodeck et al., 2002; Foroumadi et al., 2002; Sato et al., 2004; Cushnie and Lamb, 
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2005; Li et al., 2005; Ahmad et al., 2007; Aiyegoro et al., 2009). Some of these compounds 
like polyphenols have been revealed to exert their antibacterial activity through membrane 
perturbations. This perturbation of the cell membrane together with the action of β-lactams 
on the transpeptidation of the cell membrane could lead to an improved antimicrobial effect 
of the combination (Esimone et al., 2006; Sibanda and Okoh, 2008). Studies have also shown 
that some plant derived compounds can improve the in vitro activity of some peptidoglycan 
inhibiting antibiotics by directly attacking the same site in the cell wall (Zhao et al., 2001; Vu 
et al., 2002). The presence of flavonoids in plant extract could be responsible for their anti-H. 
pylori activity.  
Saponins, tannins and steroids are also very important compounds, thereby making this plant 
species a very good source of medicines and other important products. Another 
phytochemical compound observed to be present in L. javanica leaf extract is tannins. 
Tannins exert antimicrobial activities by iron deprivation, hydrogen binding or specific 
interactions with vital proteins, such as enzymes in microbial cells (Dharmananda, 2003; 
Manenzhe et al., 2004; Njume et al., 2009). According to literature, herbs that contain tannins 
are mordant in nature and are used for curing intestinal disorders, such as diarrhoea, 
dysentery and gastritis (Samie et al., 2009). Tannins have been observed to have an 
extraordinary activity in cancer deterrence (Li et al., 2003). In addition, Motal et al. (1985) 
revealed tannins to be useful in the treatment of inflamed or ulcerated tissues.  
Consequently, the existence of tannins in L. javanica supports the traditional medicinal use of 
this plant in the treatment of diseases caused by microorganisms. It was also documented by 
Just et al. (1998) that sapononis revealed inhibitory effects on inflamed cells. The leaves of L. 
javanica could be a potential source of active antimicrobial agents, and a detailed assessment 
of their in vivo potencies needs to be investigated as antibiotic resistance of microorganisms 
to infectious diseases persists. 
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5.2 CONCLUSION  
Based on the results obtained, the following conclusions can be drawn: 
1. The study demonstrated in vitro activities of the crude extracts of L. Javanica, 
acetone, methanol and ethanol extracts gave a diameter zone of inhibition of extract 
ranging from 0 – 36 mm. 
2. The MIC50 of the acetone extract of the leaves of L. javanica ranged from 0.00195 - 
0.625 mg/mL; 0.0048 - 0.625 mg/mL for metronidazole and 0.0048-1.25 mg/mL for 
amoxicillin. On the other hand, MIC90 ranged from 0.039 - 0.625 mg/mL for acetone, 
0.0097 - 5 mg/mL for metronidazole and 0.039 - 2.5 mg/mL for amoxicillin. 
3. Complete inhibition of growth of H. pylori by L. javanica ethanol extract was 
observed at 2XMIC and 4X MIC for a period of 72 hours. 
4. Phytochemical studies revealed the presence of several compounds including: 
alkaloids, flavanoids, tannins, saponnins and steroids, which could be potential 
sources for novel drugs to support the traditional medicine health care systems. 
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APPENDIX 2  
2.1 Photographs of plant species, laboratory preparations & susceptibility plates 
 
Lippia javanica plant species. 
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Dissolved plant extracts in organic solvents and water. 
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Extraction process of L. javanica using a Rotavapor system. 
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Susceptibility plates 
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Zone diameter of inhibition in agar plates. 
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APPENDIX 3  
    Statistical observation 
 
                                                         Descriptives 
MIC 50S 
 
N Mean Std. Deviation Std. Error 
95% Confidence Interval for Mean 
Minimum Maximum  Lower Bound Upper Bound 
1 29 .17305 .334951 .062199 .04564 .30046 .002 1.250 
2 29 .22513 .386543 .071779 .07810 .37216 .002 1.250 
3 26 .20040 .537861 .105483 -.01684 .41765 .002 2.500 
4 29 .11974 .267412 .049657 .01802 .22146 .005 1.250 
5 25 .11193 .272764 .054553 -.00067 .22452 .005 1.250 
Total 138 .16687 .368602 .031378 .10482 .22892 .002 2.500 
 
1=acetone, 2=methanol, 3=ethanol, 4=amoxicillin, 5=metronidazole 
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1=Acetone, 2=Methanol, 3=ethanol, 4= Amoxicillin, 5= Metronidazole 
 
 
Multiple Comparisons 
MIC 
Tukey HSD 
(I) 
Extracts 
(J) 
Extracts 
Mean Difference 
(I-J) Std. Error Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
1 2 -.052081 .097533 .984 -.32181 .21765 
3 -.027356 .100307 .999 -.30476 .25005 
4 .053309 .097533 .982 -.21642 .32304 
5 .061122 .101359 .974 -.21919 .34144 
2 1 .052081 .097533 .984 -.21765 .32181 
3 .024725 .100307 .999 -.25268 .30213 
4 .105390 .097533 .816 -.16434 .37512 
5 .113203 .101359 .797 -.16711 .39352 
3 1 .027356 .100307 .999 -.25005 .30476 
2 -.024725 .100307 .999 -.30213 .25268 
4 .080664 .100307 .929 -.19674 .35807 
5 .088478 .104031 .914 -.19923 .37618 
 
4 
1 -.053309 .097533 .982 -.32304 .21642 
2 -.105390 .097533 .816 -.37512 .16434 
3 -.080664 .100307 .929 -.35807 .19674 
5 .007814 .101359 1.000 -.27250 .28813 
5 1 -.061122 .101359 .974 -.34144 .21919 
2 -.113203 .101359 .797 -.39352 .16711 
3 -.088478 .104031 .914 -.37618 .19923 
4 -.007814 .101359 1.000 -.28813 .27250 
103 
 
 
 
 
 
 
MIC 90s 
 
N Mean Std. Deviation Std. Error 
95% Confidence Interval for Mean 
Minimum Maximum  Lower Bound Upper Bound 
1 25 .44528 .540840 .108168 .22203 .66853 .039 2.500 
2 29 .36762 .362861 .067382 .22960 .50565 .039 1.250 
3 27 .17298 .152287 .029308 .11274 .23322 .002 .625 
4 23 .43048 .534530 .111457 .19933 .66163 .039 2.500 
5 14 2.12120 2.035323 .543963 .94604 3.29636 .010 5.000 
Total 118 .55984 .975791 .089829 .38194 .73774 .002 5.000 
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Multiple Comparisons 
MIC 
Tukey HSD 
(I) 
Extracts 
(J) 
Extracts 
Mean Difference 
(I-J) Std. Error Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
1 2 .077659 .217013 .996 -.52397 .67929 
3 .272299 .220703 .732 -.33956 .88416 
4 .014802 .229744 1.000 -.62212 .65173 
5 -1.675916
*
 .265434 .000 -2.41178 -.94005 
2 1 -.077659 .217013 .996 -.67929 .52397 
3 .194639 .212653 .890 -.39490 .78418 
4 -.062858 .222022 .999 -.67837 .55266 
5 -1.753576
*
 .258779 .000 -2.47099 -1.03616 
3 1 -.272299 .220703 .732 -.88416 .33956 
2 -.194639 .212653 .890 -.78418 .39490 
4 -.257497 .225630 .784 -.88302 .36802 
5 -1.948215
*
 .261881 .000 -2.67423 -1.22220 
4 1 -.014802 .229744 1.000 -.65173 .62212 
2 .062858 .222022 .999 -.55266 .67837 
3 .257497 .225630 .784 -.36802 .88302 
5 -1.690718
*
 .269545 .000 -2.43798 -.94345 
5 1 1.675916
*
 .265434 .000 .94005 2.41178 
2 1.753576
*
 .258779 .000 1.03616 2.47099 
3 1.948215
*
 .261881 .000 1.22220 2.67423 
4 1.690718
*
 .269545 .000 .94345 2.43798 
*. The mean difference is significant at the 0.05 level. 
 
1=acetone, 2=methanol, 3=ethanol, 4=amoxicillin, 5=metronidazole 
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